Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI chatbots replace doctor questionnaires for chronic pain patients?

NCT ID NCT07336537

Knowledge-focused Sponsor: AugMend Health Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether conversational AI software can effectively collect health information from people with chronic pain. Participants will chat with a digital tool that asks about their physical symptoms, emotions, and social life. The goal is to see if patients find this approach acceptable, easy to use, and practical for real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Digital Biopsychosocial Conversational Data Collection Software (AI-powered chatbot)
What this could lead to
If successful, this could show that conversational AI is a practical way to gather detailed health information from chronic pain patients, potentially improving how their condition is understood and managed.
What could go wrong
This is a small, early-stage feasibility study (100 participants) with no control group. It only measures how acceptable and usable the software is, not whether it improves health outcomes. Technical glitches or patient discomfort with AI conversations could limit its usefulness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of chronic pain (pain lasting 3 months or longer) * Able to read and understand English * Able to provide informed consent * Willing and able to complete study procedures either at home or at the MIT.nano Immersion Lab * Access to necessary technology for home-based participation (if assigned to home-based group), or ability to travel to the MIT.nano Immersion Lab (if assigned to laboratory-based group) * Cognitively able to interact with digital data collection software and provide feedback Exclusion Criteria: * Under 18 years of age * Unable to provide informed consent * Non-English speaking * Acute pain only (pain lasting less than 3 months) * Cognitive impairment that would prevent meaningful interaction with data collection software or ability to provide valid feedback * Unable or unwilling to complete study procedures in assigned setting (home or laboratory) * Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with the participant's ability to complete study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Behavioral health challenges are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome mental disorder Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Behavioral health challenges Chronic pain Ecological momentary assessment best practices Mental health disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AugMend Health at MIT.nano Immersion Lab

    RECRUITING

    Cambridge, Massachusetts, 02139, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.